Details for New Drug Application (NDA): 016891
✉ Email this page to a colleague
The generic ingredient in TALWIN COMPOUND is aspirin; pentazocine hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; pentazocine hydrochloride profile page.
Summary for 016891
Tradename: | TALWIN COMPOUND |
Applicant: | Sanofi Aventis Us |
Ingredient: | aspirin; pentazocine hydrochloride |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 325MG;EQ 12.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes |
Expired US Patents for NDA 016891
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | TALWIN COMPOUND | aspirin; pentazocine hydrochloride | TABLET;ORAL | 016891-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription